Mei Ri Jing Ji Xin Wen·2025-07-31 23:18Group 1: Public Health Response - The 2025 version of the Chikungunya fever diagnosis and treatment plan has been released to enhance the standardized treatment level across various medical institutions in China [1] - The release reflects China's heightened vigilance towards imported infectious diseases, as there is currently no vaccine available for the virus [1] Group 2: Company Control Changes - Renfu Pharmaceutical announced a change in its actual controller to China Merchants Group, following the completion of board restructuring and control acquisition [2] - This change is expected to stabilize the company's governance structure and promote resource integration [2] Group 3: Drug Development and Approvals - Huahai Pharmaceutical's HB0043, a dual-target antibody drug, has received clinical trial approval, marking it as the first of its kind targeting IL-17A and IL-36R [3][4] - CS231295 from Microchip Biotech has received FDA approval for clinical trials, showcasing its potential in treating brain tumors due to its ability to penetrate the blood-brain barrier [4] - Shuyou Shen has obtained a summary report for BDB-001 injection, demonstrating significant clinical advantages in reducing steroid dosage for ANCA-associated vasculitis [5]